BIO

Catalog No.S7198 Synonyms: GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052

For research use only.

BIO (GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052) is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β in a cell-free assay, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor with IC50 of 30 nM for Tyk2. BIO induces apoptosis in human melanoma cells.

BIO Chemical Structure

CAS No. 667463-62-9

Selleck's BIO has been cited by 24 publications

Purity & Quality Control

Choose Selective GSK-3 Inhibitors

Other GSK-3 Products

Biological Activity

Description BIO (GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052) is a specific inhibitor of GSK-3 with IC50 of 5 nM for GSK-3α/β in a cell-free assay, shows >16-fold selectivity over CDK5, also a pan-JAK inhibitor with IC50 of 30 nM for Tyk2. BIO induces apoptosis in human melanoma cells.
Features The first pharmacological agent shown to maintain self-renewal in human and mouse embryonic stem cells.
Targets
GSK-3 [1]
(Cell-free assay)
TYK2 [4]
(Cell-free assay)
CDK5/p35 [1]
(Cell-free assay)
CDK2/CyclinA [1]
(Cell-free assay)
CDK1/CyclinB [1]
(Cell-free assay)
Click to View More Targets
5 nM 30 nM 0.08 μM 0.30 μM 0.32 μM
In vitro

BIO (6-bromoindirubin-3'-oxime) is a specific inhibitor of glycogen synthase kinase-3 (GSK-3), with IC50 of 5 nM for GSK-3α/β, shows >16-fold selectivity over CDK5. BIO interacts within the ATP binding pocket of these kinases, reduces β-catenin phosphorylation on a GSK-3-specific site in cellular models, closely mimicks Wnt signaling in Xenopus embryos. [1] In human and mouse embryonic stem cells, BIO maintains the undifferentiated phenotype and sustains expression of the pluripotent state-specific transcription factors Oct-3/4, Rex-1 and Nanog. BIO-mediated Wnt activation is functionally reversible, as withdrawal of the compound leads to normal multidifferentiation programs in both human and mouse embryonic stem cells. [2] BIO promotes proliferation in mammalian cardiomyocytes. [3]6BIO is also a pan-JAK inhibitor, with IC50 values of 0.03, 1.5, 8.0, 0.5 μM for TYK2, JAK1, JAK2 and JAK3. BIO selectively inhibits phosphorylation of STAT3 and induces apoptosis of human melanoma cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEI-OC1 NF;UUFFHfW6ldHnvckBie3OjeR?= NWXONGpxWHKxdHXjeIlwdiCjZ3HpcpN1KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGhiaX6gcoVwdmG2YXygcY92e2ViSFXJMW9EOSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4F{eGG|ZT2zM|ch[WO2aY\peJktKEWFNUCgQUAxNjF7MjFOwG0v NUDKUHBIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwPVE6OTVpPkOwNFkyQTF3PD;hQi=>
SH-SY5Y NV3TdWZ{TnWwY4Tpc44h[XO|YYm= MX3Jcohq[mm2aX;uJI9nKEeVS{OtcYVlcWG2ZXSgZoV1[S2lYYPlbY4heGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHNJNVO\NWmgZ4VtdHNiaX6gdJJme2WwY3Wgc4YhVUdzM{KgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m|LDDJR|UxKD1iMD6yPUDPxE1w MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDhzNkGxNEc,OTh6MU[xNVA9N2F-
K562 NETuWGhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M{[weVczKGi{cx?= MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDFwMzFOwG0v MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd6M{G0PUc,OTl5OEOxOFk9N2F-
IMR90 NGPYfHNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MmHGO|IhcHK| M4LVdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSV3SPVAh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGuPUDPxE1w NYmzXWs4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3PFMyPDlpPkG5O|g{OTR7PD;hQi=>
HCT116 M{f0NGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 NWTJdll3PzJiaILz M2LwbGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTC1MlIh|ryPLh?= NUHWRnc3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3PFMyPDlpPkG5O|g{OTR7PD;hQi=>
HepG2 MWnDfZRwfG:6aXPpeJkh[XO|YYm= MXeyOEBpenN? MYfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEK0JIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IEWuN{DPxE1w MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd2M{S5Nkc,Ojh5NEO0PVI9N2F-
HL60 MV;BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M3HvVlUh\GG7cx?= MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiONkCgZ4VtdHNiYX\0[ZIhPSCmYYnzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDVwNDFOwG0v NXfhV4NuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3PFMyPDlpPkG5O|g{OTR7PD;hQi=>
HuH7 NFvsZYtCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MX23NkBpenN? M1y4[GFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSIXIO{Bk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iNj6yJO69VS5? NX;QWmlORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3PFMyPDlpPkG5O|g{OTR7PD;hQi=>
SH-SY5Y NXv6XXBxS3m2b4TvfIlkcXS7IHHzd4F6 MX20PEBpenN? NELnT3hEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUC2VWUXZJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGOgdoVlfWO2aX;uJIF{e2G7LDDJR|UxKD1iOTFOwG0v NETzRms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEixOlEyOCd-MUi4NVYyOTB:L3G+
SH-SY5Y NET5ZXJHfW6ldHnvckBie3OjeR?= Mn7iOFghcHK| M4L6dHN2en[rdnHsJI9nKGi3bXHuJHNJNVO\NWmgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WUzDy[YR2[3Srb36gZZN{[XluIFnDOVAhRSB7LkWg{txONg>? MmrFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ6NUSwOlkoRjF4OEW0NFY6RC:jPh?=
SH-SY5Y MlPrSpVv[3Srb36gZZN{[Xl? MV7E[YF1cCCxZjDoeY1idiCVSD3TXVV[KGOnbHzzJIlvKGGkc3XuZ4Uhd2ZiMkCgeW0hWS2YRD3PVIgh[nliTWTTJJJm\HWldHnvckBie3OjeTygTWM2OCB;IEGwJO69VS5? NUfhd|NDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[4OVQxPjlpPkG2PFU1ODZ7PD;hQi=>
SH-SY5Y MYHGeY5kfGmxbjDhd5NigQ>? NITWOIhF\WG2aDDv[kBpfW2jbjDTTE1UYTW\IHPlcIx{KGmwIIDy[ZNmdmOnIH;mJFIxKHWPIGGtWmQuV1CqIHL5JG1VWyC{ZXT1Z5Rqd25iYYPzZZktKEmFNUCgQUAyOyEQvF2u MoXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ6NUSwOlkoRjF4OEW0NFY6RC:jPh?=
SH-SY5Y MWTGeY5kfGmxbjDhd5NigQ>? NVfTfHBKOjRiaILz NIrUeHRUfXK4aY\hcEBw\iCqdX3hckBUUC2VWUXZJINmdGy|IHHmeIVzKDJ2IHjyd{BjgSCPVGOgdoVlfWO2aX;uJIF{e2G7LDDJR|UxKD1iMUig{txONg>? M2\tSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OEW0NFY6Lz5zNki1OFA3QTxxYU6=
IMR32 NIrHXYNEgXSxdH;4bYNqfHliYYPzZZk> MXi0PEBpenN? M4\XWWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGlOWjN{IHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZk> MmL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEK5OFcoRjJzOECyPVQ4RC:jPh?=
SK-N-SH MmfQR5l1d3SxeHnjbZR6KGG|c3H5 MUi0PEBpenN? NYO0dW5ZS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0tvTj3TTEBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7 NYjue2VMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFI6PDdpPkKxPFAzQTR5PD;hQi=>
NB39 MnXWR5l1d3SxeHnjbZR6KGG|c3H5 NEK3[VY1QCCqcoO= Mn:wR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmI{QSClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgUXRVKGG|c3H5 NHfCWnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwNlk1Pyd-MkG4NFI6PDd:L3G+
A673 MmH4dWhVWyCjc4PhfS=> MkKzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN? NFnXO5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
DAOY MnfhdWhVWyCjc4PhfS=> MmT3dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN? M1rBblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2 NFfhN2RyUFSVIHHzd4F6 NXvsR5g1eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=> NV3ETnhIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37 MV3xTHRUKGG|c3H5 MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD M{fx[JFJXFNiYYPzZZk> MnrwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{ NFq4c3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH M3jqepFJXFNiYYPzZZk> NYTQNnAyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM> MoXEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-12 NWrQbmlZeUiWUzDhd5NigQ>? M1qwUZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?= NEfPOWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
MG 63 (6-TG R) NELpeoJyUFSVIHHzd4F6 M2f4cpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?= NUXae3QyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643 MWDxTHRUKGG|c3H5 MULxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
OHS-50 NWGyR|I6eUiWUzDhd5NigQ>? MXrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| NHjtdZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 NV;Rd41IeUiWUzDhd5NigQ>? NGXhOG1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh30 MUnxTHRUKGG|c3H5 MkfkdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqM{CgZ4VtdHN? NY\tT3lzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2 Ml\HdWhVWyCjc4PhfS=> MknVdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO= MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC M1\Fb5FJXFNiYYPzZZk> MVfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= NFPsVnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB-EBc1 MmnFdWhVWyCjc4PhfS=> MWPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?= Mn7BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
LAN-5 NH;PZVFyUFSVIHHzd4F6 MlOydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy| MkXkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh18 MXXxTHRUKGG|c3H5 NXzCVFdteUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO= NIDFOmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
A549 MlLKSpVv[3Srb36gZZN{[Xl? Ml:5NVAhfU1? MlPXNVUhdWmwcx?= NXm1VHN{UW6qaXLpeIlwdiCxZjDoeY1idiCvUFfFV|Eh\nKxbTDoeY1idiCDNUS5JINmdGy|IHHzd4V{e2WmIHHzJHBITTJiYYSgNVAhfU1iYX\0[ZIhOTVibXnud{BjgSCKUFzD Mn25QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4OUeyOFQoRjJ2Nkm3NlQ1RC:jPh?=
HEK293 NUTVRo1STnWwY4Tpc44h[XO|YYm= M1vNR|AvPSC2bzCxJJVO MYDJcohq[mm2aX;uJI9nKGi3bXHuJGdUUzNiYXP0bZZqfHliaX6gTGVMOjl|IHPlcIx{KGOxboThbY5qdmdidHjlJHdvfC:kZYThMYNifGWwaX6gZYN1cX[jdHXkJJJmeG:{dHXyJJBUfXCncmTPVGZNSVOKIDjTWGYzQTNiY3XscJMqKGG2IECuOUB1dyBzIIXNJIJ6KFewdDDy[ZBwenSncjDn[Y5mKGG|c3H5 NIDJ[Wo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[5O|I1PCd-MkS2PVczPDR:L3G+
sf9 NGjEWVFHfW6ldHnvckBie3OjeR?= NX;y[ndOOSC3TR?= MkHsTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCQLYTldo1qdmGuIFfTWE11[WepZXSgR2RMPCBqU{SgeI8hTTNyMzDy[ZNq\HWnczmvR5lkdGmwIFSxJEhSPCC2bzDJNlk2KHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gd4Y6KGOnbHzzJIF1KDFidV2geZNqdmdiUlKtR3RHKGG|IIP1ZpN1emG2ZTDifUBncWy2ZYKgZolv\GmwZzDhd5NigQ>? Ml;KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NUe0N|AoRjJ6NUW3OFMxRC:jPh?=
sf9 MVzGeY5kfGmxbjDhd5NigQ>? MV2xJJVO MkS0TY5pcWKrdHnvckBw\iCqdX3hckBPNXSncn3pcoFtKEeVVD;IbZM3NXSjZ3fl[EBIW0t|YnX0ZUApVTFidH:gWFQzOCC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKHOoOTDj[YxteyCjdDCxJJVOKHW|aX7nJHJDTVJvSWLTeIll\SCjczDzeYJ{fHKjdHWgZpkh\mmudHXyJIJqdmSrbnegZZN{[Xl? NXq1V|NPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OVc1OzBpPkK4OVU4PDNyPD;hQi=>
sf9 MUTGeY5kfGmxbjDhd5NigQ>? MlTHNUB2VQ>? NFn0N4ZKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIF6teIVzdWmwYXygS3NVNXSjZ3fl[EBETEt{IDjNNUB1dyCOMkm4JJJme2mmdXXzLU9EgWOuaX6gRVIhME1zIITvJGw1OzJicnXzbYR2\XNrIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CC|ZkmgZ4VtdHNiYYSgNUB2VSC3c3nu[{BJcXO2b37lJGgyKGG|IIP1ZpN1emG2ZTDifUBncWy2ZYKgZolv\GmwZzDhd5NigQ>? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV3N{SzNEc,Ojh3NUe0N|A9N2F-
sf9 MmP3SpVv[3Srb36gZZN{[Xl? NEHuUmEyKHWP MWPJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKE5vdHXycYlv[WxiR2PUMZRi\2enZDDDSGs2KCiPMTD0c{BROjl{IILld4llfWW|KT;wN|VPS0tiKF2xJJRwKFJ|MEegdoV{cWS3ZYOpJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDz[lkh[2WubIOgZZQhOSC3TTD1d4lv\yCUQj3DWGYh[XNic4Xid5Rz[XSnIHL5JIZqdHSncjDibY5lcW6pIHHzd4F6 NWrVTGxpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OVc1OzBpPkK4OVU4PDNyPD;hQi=>
sf9 MoXGSpVv[3Srb36gZZN{[Xl? MkjuNUB2VQ>? M1vLVGlvcGmkaYTpc44hd2ZiaIXtZY4hVi22ZYLtbY5idCCJU2SvTIl{Pi22YXfn[YQhSXW{b4LhJGIhMEF{IITvJGE{PDRicnXzbYR2\XNrIHX4dJJme3OnZDDpckB{\jliY3XscJMh[XRiMTD1UUB2e2mwZzD0[ZRz[SiOUmLMV2xIMSCjczDzeYJ{fHKjdHWgZpkh\mmudHXyJIJqdmSrbnegZZN{[Xl? NH\WW|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW1O|Q{OCd-Mki1OVc1OzB:L3G+
sf9 M{i5OmZ2dmO2aX;uJIF{e2G7 NFv3dVEyKHWP NV7HPJRRUW6qaXLpeIlwdiCxZjDoeY1idiCQLYTldo1qdmGuIFfTWE9JcXN4LYTh[4dm\CCIR1\SNUApTzRyMDD0c{BTQDJyIILld4llfWW|KTDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRic3[5JINmdGy|IHH0JFEhfU1idYPpcochWG:ueTjHcJUtXHm{KUS6NUBieyC|dXLzeJJifGViYomg[oltfGW{IHLpcoRqdmdiYYPzZZk> NGfVcm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW1O|Q{OCd-Mki1OVc1OzB:L3G+
sf9 NUP1UZpyTnWwY4Tpc44h[XO|YYm= MUOxJJVO M{PYdWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDHV3QwUGm|Nj30ZYdo\WRiQ1TLNUApVTFidH:gUVI6PyC{ZYPp[JVmeylxQ4njcIlvKEJzIDjNNUB1dyCYNEOzJJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5ic3[5JINmdGy|IHH0JFEhfU1idYPpcochWkJvQ2TGJIF{KHO3YoP0doF1\SCkeTDmbYx1\XJiYnnu[Ilv\yCjc4PhfS=> MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV3N{SzNEc,Ojh3NUe0N|A9N2F-
sf9 MXjGeY5kfGmxbjDhd5NigQ>? MYWxJJVO M3XxS2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDHV3QufGGpZ3XkJGNFUzJiKF2xJJRwKEx{OUigdoV{cWS3ZYOpM2N6[2yrbjDFNUApVTFidH:gRVM6PSC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJJNnQSClZXzsd{BifCBzIIXNJJV{cW6pIGLCMWNVTiCjczDzeYJ{fHKjdHWgZpkh\mmudHXyJIJqdmSrbnegZZN{[Xl? MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV3N{SzNEc,Ojh3NUe0N|A9N2F-
sf9 NWrTXFNOTnWwY4Tpc44h[XO|YYm= MlL4NUB2VQ>? MVnJcohq[mm2aX;uJI9nKGi3bXHuJG4ufGW{bXnuZYwhT1OWL1jpd|YufGGpZ3XkJGF2em:{YTDBJEhOOSC2bzDTOFA{KHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhe2Z7IHPlcIx{KGG2IEGgeW0hfXOrbnegeIV1emFqTGLSUHNNTyliYYOgd5Vje3S{YYTlJIJ6KG[rbITldkBjcW6maX7nJIF{e2G7 NGfuXZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW1O|Q{OCd-Mki1OVc1OzB:L3G+
sf9 NX3vbVA3TnWwY4Tpc44h[XO|YYm= MWSxJJVO NH32NYpKdmirYnn0bY9vKG:oIHj1cYFvKE5vdHXycYlv[WxiR2PUMZRi\2enZDDBeZJwemFiQjCoUVEhfG9iU{K3JJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5ic3[5JINmdGy|IHH0JFEhfU1idYPpcochS0SFMkXDMYRmemm4ZXSgdIVxfGmmZTDhd{B{fWK|dILheIUh[nliZnnseIVzKGKrbnTpcoch[XO|YYm= NF74fGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW1O|Q{OCd-Mki1OVc1OzB:L3G+
HT22 NHTLSmZHfW6ldHnvckBie3OjeR?= MnrQNVAhfU1? NU[zbW9EOjRiaILz NH\vdm5KdmirYnn0bY9vKG:oIFfTT|MudWWmaXH0[YQh[mW2YTDjZZNmcW5icHjvd5Bpd3K7bHH0bY9vKGmwIH3veZNmKEiWMkKgZ4VtdHNiYYSgNVAhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrczDpckBxemW|ZX7j[UBw\iCPR{GzNi=> MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl7OES0N{c,OjJ7OUi0OFM9N2F-
Assay
Methods Test Index PMID
Western blot p-AKT / AKT / p21 / p27 ; p-β-catenin / β-catenin ; FoxO3a / FoxO1 / p-FoxO3a / p-FoxO1 27510556 27211495
Immunofluorescence pAKT / p21 / p27 ; TNF-α ; E-cadherin / Nanog ; Oct3/4 27510556 24286133 25538040
Growth inhibition assay Cell proliferation 27510556
In vivo BIO suppresses melanoma tumor growth in a mouse xenograft model. [4]

Protocol (from reference)

Kinase Assay:[1]
  • Kinase assay:

    Kinase activities are assayed in Buffer A or C at 30°C, at a final ATP concentration of 15 μM. Blank values are subtracted and activities calculated as pmoles of phosphate incorporated during a 10 min incubation. Controls are performed with appropriate dilutions of dimethylsulfoxide. In a few cases phosphorylation of the substrate is assessed by autoradiography after SDS-PAGE. GSK-3α/β is purified from porcine brain by affinity chromatography on immobilized axin. It is assayed, following a 1/100 dilution in 1 mg BSA/ml 10 mM DTT, with 5 μl 40 μM GS-1 peptide, a specific GSK-3 substrate, (YRRAAVPPSPSLSRHSSPHQSpEDEEE), in buffer A, in the presence of 15 μM [γ-32P] ATP (3,000 Ci/mmol; 1 mCi/ml) in a final volume of 30 μl. After 30 min incubation at 30°C, 25 μl aliquots of supernatant are spotted onto 2.5 × 3 cm pieces of Whatman P81 phosphocellulose paper, and 20 seconds later, the filters are washed five times (for at least 5 min each time) in a solution of 10 ml phosphoric acid/liter of water. The wet filters are counted in the presence of 1 ml ACS scintillation fluid.

Cell Research:[1]
  • Cell lines: COS1, Hepa or SH-SY5Y cells
  • Concentrations: ~10 μM
  • Incubation Time: 12 or 24 h
  • Method: COS1, Hepa (wild-type, CEM/LM AhR deficient and ELB1 ARNT deficient), or SH-SY5Y cells are grown in 6 cm culture dishes in Dulbecco's Modified Medium (DMEM) containing 10% fetal bovine serum. For treatment, IO (5 μM), BIO (5 or 10 μM), MeBIO (5 or 50 μM), LiCl (20 or 40 mM), or mock solution (DMSO, 0.5% final concentration) is added to medium when cell density reaches ∼70% confluence. After 12 (SH-SY5Y) or 24 hours, the cells, while still in plate, are lysed with lysis buffer (1% SDS, 1 mM sodium orthovanadate, 10 mM Tris [pH 7.4]). The lysate is passed several times through a 26G needle, centrifuged at 10,000 × g for 5 min, and adjusted to equal protein concentration. About 8 μg of each sample is loaded for immunoblotting. Enhanced chemiluminescence is used for detection. The following primary antibodies are used: mouse anti-β-catenin CT (Upstate Biotechnolgies, Clone 7D8, recognizes total β-catenin), mouse anti-phospho-β-catenin (Upstate Biotechnologies, Clone 8E7, recognizes dephosphorylated β-catenin), mouse anti-GSK-3 β, mouse anti-GSK-3 phosphoTyr216, rabbit anti-AhR (Aryl hydrocarbon receptor), and rabbit anti-actin.
  • (Only for Reference)
Animal Research:[4]
  • Animal Models: mouse
  • Dosages: 50 mg/kg
  • Administration: Oral gavage
  • (Only for Reference)

Solubility (25°C)

In vitro

DMSO 71 mg/mL
(199.34 mM)
Water Insoluble
Ethanol '6 mg/mL

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+50%ddH2O
For best results, use promptly after mixing.

3 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 356.17
Formula

C16H10BrN3O2

CAS No. 667463-62-9
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=CC=C2C(=C1)C(=C(N2)C3=C(NC4=C3C=CC(=C4)Br)O)N=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04276857 Not yet recruiting Device: Irreversible electroporation (NanoKnife® ) Locally Advanced Pancreatic Cancer|Irreversible Electroporation University of Saskatchewan April 1 2022 Not Applicable
NCT04461301 Not yet recruiting Procedure: Multimodal Prehabilitation Frail Elderly Syndrome|Major Surgery University Hospital Inselspital Berne|University of Bern February 1 2022 Not Applicable
NCT05085730 Not yet recruiting Device: InMode Morpheus8 System Aging University of Texas Southwestern Medical Center February 1 2022 Not Applicable

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy BIO | BIO supplier | purchase BIO | BIO cost | BIO manufacturer | order BIO | BIO distributor